Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more
Ocular Therapeutix Inc (OCUL) - Net Assets
Latest net assets as of December 2025: $654.31 Million USD
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has net assets worth $654.31 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($808.06 Million) and total liabilities ($153.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $654.31 Million |
| % of Total Assets | 80.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | 643.54% |
| 10-Year Change | 1158.09% |
| Growth Volatility | 104.24 |
Ocular Therapeutix Inc - Net Assets Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual net assets of Ocular Therapeutix Inc from 2012 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $654.31 Million | +107.49% |
| 2024-12-31 | $315.34 Million | +246.03% |
| 2023-12-31 | $91.13 Million | +157.59% |
| 2022-12-31 | $35.38 Million | -59.80% |
| 2021-12-31 | $88.00 Million | +15.64% |
| 2020-12-31 | $76.09 Million | +2196.28% |
| 2019-12-31 | $-3.63 Million | -110.12% |
| 2018-12-31 | $35.88 Million | +37.21% |
| 2017-12-31 | $26.15 Million | -49.73% |
| 2016-12-31 | $52.01 Million | -41.95% |
| 2015-12-31 | $89.59 Million | +52.63% |
| 2014-12-31 | $58.70 Million | +198.70% |
| 2013-12-31 | $-59.47 Million | -27.59% |
| 2012-12-31 | $-46.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ocular Therapeutix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 110956000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $22.00K | 0.00% |
| Other Components | $1.81 Billion | 276.83% |
| Total Equity | $654.31 Million | 100.00% |
Ocular Therapeutix Inc Competitors by Market Cap
The table below lists competitors of Ocular Therapeutix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
$1.86 Billion |
|
VALIF
PINK:VALIF
|
$1.86 Billion |
|
Caris Life Sciences, Inc. Common Stock
NASDAQ:CAI
|
$1.86 Billion |
|
KRUK SA ZY 1
F:83I
|
$1.86 Billion |
|
Swatch Group AG Class N
SW:UHRN
|
$1.86 Billion |
|
Per Aarsleff Holding A/S
CO:PAAL-B
|
$1.86 Billion |
|
Wuhu Token Sciences
SHE:300088
|
$1.86 Billion |
|
Harbin Electric
F:HP6H
|
$1.85 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ocular Therapeutix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 315,344,000 to 654,310,000, a change of 338,966,000 (107.5%).
- Net loss of 265,939,000 reduced equity.
- Share repurchases of 1,592,000 reduced equity.
- New share issuances of 541,177,000 increased equity.
- Other factors increased equity by 65,320,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-265.94 Million | -40.64% |
| Share Repurchases | $1.59 Million | -0.24% |
| Share Issuances | $541.18 Million | +82.71% |
| Other Changes | $65.32 Million | +9.98% |
| Total Change | $- | 107.49% |
Book Value vs Market Value Analysis
This analysis compares Ocular Therapeutix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-15.79 | $8.63 | x |
| 2013-12-31 | $-20.14 | $8.63 | x |
| 2014-12-31 | $5.51 | $8.63 | x |
| 2015-12-31 | $3.85 | $8.63 | x |
| 2016-12-31 | $2.10 | $8.63 | x |
| 2017-12-31 | $0.91 | $8.63 | x |
| 2018-12-31 | $0.94 | $8.63 | x |
| 2019-12-31 | $-0.08 | $8.63 | x |
| 2020-12-31 | $1.25 | $8.63 | x |
| 2021-12-31 | $1.07 | $8.63 | x |
| 2022-12-31 | $0.43 | $8.63 | x |
| 2023-12-31 | $1.06 | $8.63 | x |
| 2024-12-31 | $1.99 | $8.63 | x |
| 2025-12-31 | $3.49 | $8.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ocular Therapeutix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -40.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -513.17%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.23x
- Recent ROE (-40.64%) is above the historical average (-84.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | -140930.00% | 0.00x | 0.00x | $-9.43 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.37 Million |
| 2014 | -48.81% | -3710.88% | 0.01x | 1.33x | $-34.52 Million |
| 2015 | -44.37% | -2271.31% | 0.02x | 1.23x | $-48.71 Million |
| 2016 | -85.95% | -2369.00% | 0.03x | 1.44x | $-49.90 Million |
| 2017 | -242.42% | -3296.20% | 0.03x | 2.12x | $-66.00 Million |
| 2018 | -160.81% | -2899.10% | 0.03x | 2.04x | $-61.28 Million |
| 2019 | 0.00% | -2043.34% | 0.05x | 0.00x | $-86.01 Million |
| 2020 | -204.53% | -894.31% | 0.07x | 3.44x | $-163.25 Million |
| 2021 | -7.45% | -15.06% | 0.21x | 2.33x | $-15.35 Million |
| 2022 | -200.79% | -137.95% | 0.34x | 4.22x | $-74.58 Million |
| 2023 | -88.59% | -138.14% | 0.23x | 2.77x | $-89.85 Million |
| 2024 | -61.36% | -303.67% | 0.14x | 1.45x | $-225.04 Million |
| 2025 | -40.64% | -513.17% | 0.06x | 1.23x | $-331.37 Million |
Industry Comparison
This section compares Ocular Therapeutix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ocular Therapeutix Inc (OCUL) | $654.31 Million | 0.00% | 0.23x | $1.86 Billion |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |